The psychedelic renaissance: the next trip for psychiatry?
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
The psychedelic research renaissance is gaining traction. Preliminary clinical studies of the hallucinogenic fungi, psilocybin, with psychological support, have indicated improvements in mood, anxiety and quality of life. A seminal, open-label study demonstrated marked reductions in depression symptoms in participants with treatment-resistant depression (TRD). The associated neurobiological processes involve alterations in brain connectivity, together with altered amygdala and default mode network activity. At the cellular level, psychedelics promote synaptogenesis and neural plasticity. Prompted by the promising preliminary studies, a randomized, double-blind trial has recently been launched across Europe and North America to investigate the efficacy of psilocybin in TRD. One of these centres is based in Ireland – CHO Area 7 and Tallaght University Hospital. The outcome of this trial will determine whether psilocybin with psychological support will successfully translate into the psychiatric clinic for the benefit of patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 2×
“Moreover, these effects were sustained at 6-month follow-up in 80% of the participants (Grob et al. 2011; Griffiths et al. 2016).”
Resting-state connectivity biomarkers define neurophysiological subtypes of depression
Drysdale, A. T., Grosenick, L., Downar, J., Dunlop, K., Mansouri, F., Meng, Y., Fetcho, R. N., Zebley, B., Oathes, D. J., Etkin, A., et al. (2017) · Nature Medicine · doi:10.1038/nm.4246 · Cited by 2,170 · cited 1×
“It will be fascinating to see whether psilocybin with psychological support will play a role in a systems-based personalized psychiatry paradigm (Insel et al. 2010; Drysdale et al. 2017; Kelly et al. 2017b; Kelly et al. 2019a; Kelly et al. 2019b; Tokuda et al. 2018).”
BackgroundRoss, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“Griffiths and colleagues reported that, in healthy hallucinogen-naive adults, psilocybin led to profound experiences of personal ‘meaning’ and ‘spiritual’ significance (Griffiths et al. 2006).”
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540
Daselaar, S. M. (2009) · Frontiers in Human Neuroscience · doi:10.3389/neuro.09.013.2009 · Cited by 1,501
Psychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119598109 · Cited by 1,172 · cited 1×
“A ‘reset’ mechanism has been proposed by which a decrease in DMN integrity during the psychedelic experience (Carhart-Harris et al. 2012; Palhano-Fontes et al. 2015; Carhart-Harris et al. 2016b) may increase or normalize in the post-acute period (1 day post-dose) accompanied by improvements in mood (Carhart-Harris et…”
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151 · cited 1×
“2017) and alcohol addiction (Krebs and Johansen, 2012; Bogenschutz et al .”
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
Depressive rumination, the default-mode network, and the dark matter of clinical neuroscience
Hamilton, J. P., Farmer, M., Fogelman, P., & Gotlib, I. H. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2015.02.020 · Cited by 952 · cited 1×
“DMN integrity has been linked to many complex psychological processes, including depressive rumination (Hamilton et al. 2015).”
BackgroundPilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914 · cited 1×
“Other research groups have utilized the altered perspective induced by psychedelic-assisted psychotherapy to help people overcome tobacco (Johnson et al. 2014; Johnson et al. 2017) and alcohol addiction (Krebs and Johansen, 2012; Bogenschutz et al.”
Neural correlates of the LSD experience revealed by multimodal neuroimaging
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L., Kaelen, M., Droog, W., Murphy, K., Tagliazucchi, E., Schenberg, E. E., Nest, T., Orban, C., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1518377113 · Cited by 859
Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31551-4 · Cited by 795
Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 1×
“Preliminary evidence also suggests that obsessive– compulsive disorder may also benefit from psilocybin administered in a controlled environment (Moreno et al. 2006).”
BackgroundLong-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Psychedelics and the essential importance of context
Carhart-Harris, R. L., Roseman, L., Haijen, E., Erritzoe, D., Watts, R., Branchi, I., & Kaelen, M. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118754710 · Cited by 657 · cited 1×
“The building of a trusting relationship with the team and particularly with the therapist, who encourages and supports the participants, is pivotal to maximize the therapeutic effect, while minimizing the risk of adverse events (Carhart-Harris et al. 2018b).”
BackgroundPsilocybin for treatment-resistant depression: fMRI-measured brain mechanisms
Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., Tanner, M., Kaelen, M., McGonigle, J., Murphy, K., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13282-7 · Cited by 587 · cited 6×
“Indeed, the antidepressant effects of psilocybin have been demonstrated 1 day post-dose (Carhart-Harris et al. 2017).”
InfluentialLysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials
Krebs, T. S., & Johansen, P.-Ø. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112439253 · Cited by 583 · cited 1×
“2017) and alcohol addiction (Krebs and Johansen, 2012; Bogenschutz et al .”
Psychiatry beyond the current paradigm
Bracken, P., Thomas, P., Timimi, S., Asen, E., Behr, G., Beuster, C., Bhunnoo, S., Browne, I., Chhina, N., Double, D., et al. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.109447 · Cited by 474 · cited 1×
“synergistically combining psychotherapy and psychopharmacology, this RCT has the potential to evolve treatments beyond the regrettable, but lingering, dichotomy of ‘biological’ and ‘psycho-environmental’ (Bracken et al. 2012; Dunlop et al. 2019).”
Palhano-Fontes, F., Andrade, K. C., Tofoli, L. F., Santos, A. C., Crippa, J. A. S., Hallak, J. E. C., Ribeiro, S., & de Araujo, D. B. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118143 · Cited by 454
Ketamine: 50 Years of Modulating the Mind
Li, L., & Vlisides, P. E. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00612 · Cited by 385 · cited 1×
“A rare, but successful example of translation into clinical utility is the re-purposing of ketamine, first synthesized in 1956 (Li and Vlisides, 2016).”
BackgroundKelly, J. R., Allen, A. P., Temko, A., Hutch, W., Kennedy, P. J., Farid, N., Murphy, E., Boylan, G., Bienenstock, J., Cryan, J. F., et al. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.11.018 · Cited by 355 · cited 1×
“2016; Kelly et al .”
Self-citationJohnson, M. W., Griffiths, R. R., Hendricks, P. S., & Henningfield, J. E. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.05.012 · Cited by 354 · cited 1×
“Compared toother recreational substances, psilocybin is among the least harmful, with minor physiological side effects and minimal reinforcing effects (Krebs and Johansen, 2013; Hendricks et al. 2015; Johansen and Krebs, 2015; Johnson et al. 2018).”
BackgroundPsychedelics and mental health: a population study
Krebs, T. S., & Johansen, P.-Ø. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063972 · Cited by 347
Effects of psilocybin therapy on personality structure
Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart‐Harris, R. L. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12904 · Cited by 267
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266 · cited 1×
“At the cellular level, psy-chedelics act as ‘ psychoplastogens ’ , a relatively new class of fast-acting therapeutics capable of rapidly promoting structural and functional neural plasticity (Catlow et al .”
A systematic study of microdosing psychedelics
Polito, V., & Stevenson, R. J. (2019) · PLoS ONE · doi:10.1371/journal.pone.0211023 · Cited by 235 · cited 2×
“This renaissance, and the enthusiasm among the general population (Polito and Stevenson, 2019), has left some professionals nonplussed.”
BackgroundIncreased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.041 · Cited by 230 · cited 1×
“At the neuroimaging level, psychedelics alter brain connectivity (Carhart-Harris, 2019), and activity in the amygdala (Roseman et al. 2018) and default mode network (DMN) (Carhart-Harris et al.”
Identification of depression subtypes and relevant brain regions using a data-driven approach
Tokuda, T., Yoshimoto, J., Shimizu, Y., Okada, G., Takamura, M., Okamoto, Y., Yamawaki, S., & Doya, K. (2018) · Scientific Reports · doi:10.1038/s41598-018-32521-z · Cited by 136
Reiche, S., Hermle, L., Gutwinski, S., Jungaberle, H., Gasser, P., & Majić, T. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.09.012 · Cited by 122 · cited 1×
“The findings in terminally ill cancer patients have been reproduced by other research groups (Ross et al. 2016; Reiche et al. 2018).”
Result
Cited by
Default Mode Network Modulation by Psychedelics: A Systematic Review
Gattuso, J. J., Perkins, D., Ruffell, S., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L. A., et al. (2023) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac074 · Cited by 256
“Brain entropy is characterized by increased randomness, unpredictability, and disorderliness (with respect to neuronal firing), which in turn disrupts top-down, goal-oriented cognitive processing (Carhart-Harris, 2018, 2019; Kelly et al., 2019; Varley et al., 2020).”
BackgroundPsychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84
Self-citationPsychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
Self-citationFrymann, T., Whitney, S., Yaden, D. B., & Lipson, J. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.863247 · Cited by 30
“…renaissance,” with rates of usage among adults increasing steadily along with the revival of psychedelic research (Krebs and Johansen, 2013; Kelly et al., 2019; Aday et al., 2020; Yockey et al., 2020; Killion et al., 2021; Palamar et al., 2021), warranting caution for both…”
Background
Metadata
- Authors
- Kelly, J. R., Baker, A., Babiker, M., Burke, L., Brennan, C., & O’Keane, V.
- Venue
- Irish Journal of Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2019-09-23
- Volume
- 39
- Issue
- 4
- Pages
- 335-339
- ISSN
- 0790-9667 (ISSN-L)
- 2051-6967
- OpenAlex
- W2975755375
- Cited by
- 21
- References
- 32
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.